We are joined by Alessandra Tedeschi at EHA 2019 to discuss her presentation on the five-year follow-up of patients receiving ibrutinib for first-line treatment of chronic lymphocytic leukemia (CLL).
1. How does ibrutinib fit into the treatment paradigm for chronic lymphocytic leukemia? (0:05)
2. What were the major findings of the long-term follow-up of the RESONATE-2 study? (0:27)
3. Which patient subgroups were most likely to experience durable responses? (1:09)
4. What is the long-term safety profile of ibrutinib? (1:38)
5. What are the treatment options for patients who discontinue ibrutinib therapy? (2:13)
Alessandra Tedeschi has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Elias Jabbour, ASH 2021: Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (PACE and OPTIC Trials)
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!